Oncology Medical News about Hearing sensitivity, breast cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Hearing sensitivity in women following chemotherapy treatment for breast cancer: Results from a pilot study
The Breast, 08/21/09

Jenkins V et al. - In a study to examine whether standard adjuvant treatments for breast cancer can adversely affect hearing, it was revealed that variability noted in the data is more than that would be anticipated for test–retest variance, suggesting that hearing impairments are complex but genuine. Most likely cause of the reduction in hearing sensitivity is a change in oestrogen levels resulting from breast cancer treatments.

Methods

8 pre/peri-menopausal women with breast cancer had middle ear analysis (tympanometry) and pure tone audiometry conducted prior to and 6 mos following fluorouracil, epirubicin, cyclophosphamide (FEC) or FEC plus taxotere chemotherapy treatments.

Results

Mean hearing thresholds in both ears showed an elevation (that is a decline) post-chemotherapy treatment at 6 and 8 kHz of between 20 and 30 dB, which is graded as a mild hearing impairment at the higher frequency range.
There were individual differences in pattern and grade within the group.

<< Previous
Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal...

Next >>
Activity of ixabepilone in oestrogen receptor-negative and...